Association of GLP-1 Receptor Agonist Use With Chronic Kidney Disease Risk in Type 2 Diabetes: Multicenter Emulated Target Trials
Listen to this summary
The authors aimed to determine whether the initiation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk of chronic kidney disease (CKD) compared to dipeptidyl peptidase-4 inhibitors (DPP-4is) in patients with type 2 diabetes (T2D) who do not have pre-existing CKD. Their findings indicate that GLP-1 RA users experienced significantly lower risks of composite kidney outcomes, incident CKD, acute kidney injury, major adverse cardiac events, and all-cause mortality compared to those using DPP-4is.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from Mayo Clinic proceedings
View all →May 8, 2026 · Mayo Clinic proceedings
Gut Oxalate Transport and Gut Microbiome as Potential Therapeutic Targets for Hyperoxaluria and Hyperoxalemia: Implications for Related Human Disease
May 7, 2026 · Mayo Clinic proceedings
Hybrid Quantum-Classical Model That Combines Spatial-Temporal EEG and Digitized Counterdiabatic Quantum Features for Motor Imagery Classification
May 2, 2026 · Mayo Clinic proceedings
Consensus Recommendation: Real World Insights on Attitudes and Treatment of Hyperkalemia
May 2, 2026 · Mayo Clinic proceedings
Resting Heart Rate is an Independent Prognostic Marker for Cancer Mortality and a Modifiable Target of Physical Activity: A Prospective Cohort Study From 615,730 Asian Participants
May 1, 2026 · Mayo Clinic proceedings
Heart Failure Phenotypes and the Prognostic Utility of NT-proBNP in Patients With Chronic Kidney Disease: A Propensity-Score Matched Cohort Study
May 1, 2026 · Mayo Clinic proceedings
On the Spectrum: High-Functioning Autism and Its Contemporary Relevance
More in Internal Medicine
View all →May 10, 2026 · JAMA
Digoxin in Patients With Symptomatic Rheumatic Heart Disease: A Randomized Clinical Trial
May 10, 2026 · European heart journal
Blinded withdrawal of randomized treatment with low-dose digoxin or placebo in patients with heart failure: the DECISION trial
May 10, 2026 · Lancet (London, England)
Endovascular thrombectomy for patients with large-core ischaemic stroke presenting up to 24 h after onset (ATLAS): a systematic review and individual patient data meta-analysis with central imaging adjudication
May 10, 2026 · European heart journal
Renin-angiotensin-aldosterone system inhibition and haemocompatibility-related adverse events in patients with durable left ventricular assist device: the MOMENTUM-3 trial
May 10, 2026 · JAMA
Efficacy and Safety of Digitalis Glycosides in Heart Failure: A Meta-Analysis
May 10, 2026 · Lancet (London, England)
Impact of introducing RTS,S/AS01<sub>E</sub> malaria vaccine on mortality in young children in Ghana, Kenya, and Malawi: an observational evaluation of a cluster-randomised implementation programme
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
